WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling [0.03%]
WDR1通过Wnt/β-连环蛋白信号促进前列腺癌进展
Jinfeng Cheng,Dan Huo,Zhonghua Zhang et al.
Jinfeng Cheng et al.
Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer-related death among men. A comprehensive understanding of PCa progression is crucial for the development of innovative therapeutic strategies for i...
Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma [0.03%]
转移性肾细胞癌一线免疫治疗联合疗法的临床疗效与肿瘤微环境的关系
Enrico Sammarco,Martina Rossetti,Alessia Salfi et al.
Enrico Sammarco et al.
The impact of tumor microenvironment (TME) in influencing clinical response to first-line immune checkpoint inhibitor (ICI)-based treatment in advanced renal cell carcinoma (RCC) is unclear. Immunohistochemistry (IHC) could identify biomark...
Effective delivery of anti-PD-L1 siRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines [0.03%]
人重链铁蛋白(HFn)在急性髓系白血病细胞系中有效传递抗PD-L1 siRNA
Misagh Rajabinejad,Reza Valadan,Mohsen Tehrani et al.
Misagh Rajabinejad et al.
Because of the high biocompatibility, self-assembly capability, and CD71-mediated endocytosis, using human heavy chain ferritin (HFn) as a nanocarrier would greatly increase therapeutic effectiveness and reduce possible adverse events. Anti...
A small molecule compound 759 inhibits the wnt/beta-catenin signaling pathway via increasing the Axin protein stability [0.03%]
一种小分子化合物759通过增加Axin蛋白稳定性抑制Wnt/β-catenin信号通路
Seunghan Sun,Young-Dae Gong,Jong Soon Kang et al.
Seunghan Sun et al.
Wnt/β-catenin signaling plays important role in cancers. Compound 759 is one of the compounds previously screened to identify inhibitors of the Wnt/β-catenin pathway in A549 cells [Lee et al. in Bioorg Med Chem Lett 20:5900-5904, 2010]. H...
Evaluation of the cytotoxic activities of the essential oil from Pistacia atlantica Desf. oleoresin on human gastric cancer cell lines [0.03%]
评价Pistacia atlantica Desf. 杉科的油树脂对人类胃癌细胞系毒性作用的影响
Fatemeh Saeedi,Mohammad Salehi,Mohammad Javad Kamali et al.
Fatemeh Saeedi et al.
Numerous herbal products have been the subject of research regarding their potential role in cancer prevention or adjuvant therapy. Pistacia atlantica and its main phytochemicals have garnered significant attention for their potential anti-...
Harnessing polyelectrolyte complexes for precision cancer targeting: a comprehensive review [0.03%]
用于精准癌症治疗的聚电解质复合物的研究进展综述
Bhupendra G Prajapati,Jai Bharti Sharma,Swapnil Sharma et al.
Bhupendra G Prajapati et al.
Polyelectrolytes represent a unique class of polymers abundant in ionizable functional groups. In a solution, ionized polyelectrolytes can intricately bond with oppositely charged counterparts, giving rise to a fascinating phenomenon known ...
In vitro study on anti-proliferative and anti-cancer activity of picrosides in triple-negative breast cancer [0.03%]
穿心莲内酯体外抗三阴性乳腺癌增殖和促凋亡作用的研究
Deepika Soni,Divya Wahi,Saurabh Verma
Deepika Soni
Picrorhiza kurroa, an "Indian gentian," a known Himalayan medicinal herb with rich source of phytochemicals like picrosides I, II, and other glycosides, has been traditionally used for the treatment of liver and respiratory ailments. Picros...
Phytochemical profiling, cytotoxic, anti-migration, and anti-angiogenic potential of phenolic-rich fraction from Peganum harmala: in vitro and in ovo studies [0.03%]
富含酚类组分的阿魏苦豆子植物化学成分定性分析及其体外和在位试验细胞毒性、抗迁移和抗血管生成潜能研究
Hadjer Kemel,Lamia Benguedouar,Djamel Boudjerda et al.
Hadjer Kemel et al.
Peganum harmala has been extensively employed in Algerian traditional medicine practices. This study aimed to explore the impact of n-butanol (n-BuOH) extract sourced from Peganum harmala seeds on cell proliferation, cell migration, and ang...
Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells [0.03%]
Aurora激酶抑制剂与ABL酪氨酸激酶抑制剂asciminib联合用于ABL抑制剂耐药的CML细胞治疗
Seiichi Okabe,Mitsuru Moriyama,Akihiko Gotoh
Seiichi Okabe
The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myeloid leukemia (CML). However, resistance to ABL TKIs can develop in CML patients due to BCR::ABL1 point mutation...